Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Operating Cash Flow
Cash generated by the company's core business operations during the period.
Pelthos Therapeutics Inc.AMEX: PTHS
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $13.13M (cash outflow) rose 1976.5% year over year, ahead of the +691.5% change in trailing-twelve-month operating cash flow. Sequentially, it rose 109.9% from the prior quarter. Over 3 fiscal years it compounded at +143.4% a year.
Context
- Operating cash flow amounted to 134.5% of revenue in FY2025.
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1976.5% holds above the trailing-twelve-month pace of +691.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (22.59M) USD
- Year-over-year change
- -290.0%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.59M) | -290.0% |
| FY2024 | 2024-12-31 | (5.79M) | -490.4% |
| FY2023 | 2023-12-31 | (981.03K) | +37.4% |
| FY2022 | 2022-12-31 | (1.57M) | — |
Operating Cash Flow vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's LTM Mar 2026 operating cash flow of $35.08M is the largest of the 4 companies compared; the peer median is $10.69M.
- Its year-over-year change of +691.5% is the highest of 4, against a peer median of +36.6%.
- Operating cash flow amounts to 126.7% of revenue for PTHS.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.08M | +691.5% | +143.4% | 126.7% | |
| LTM Mar 2026 | $19.55M | +36.6% | +2.8% | — | |
| LTM Dec 2025 | $10.69M | -17.8% | -24.2% | — | |
| LTM Mar 2026 | $4.33M | +47.2% | -12.7% | — | |
| Peer median (excluding PTHS) | $10.69M | +36.6% | -12.7% | — | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (2.46M) | (7.38M) | (7.96M) | (43.32M) |
| Depreciation & Amortization | 0 | 0 | 0 | 2.36M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 110.15K | 1.73M | 1.8M | 0 |
| Change in Working Capital | 640.86K | 2.05M | 34.63K | (6.07M) |
| Accounts Receivables | 0 | 0 | (45.79K) | (8.81M) |
| Inventory | 0 | 0 | 0 | 1.78M |
| Accounts Payables | 413.6K | 1.63M | 1.18M | 1.36M |
| Other Working Capital | 227.26K | 424.07K | (1.1M) | (395K) |
| Other Non-Cash Items | 140.43K | 2.62M | 328.93K | 24.44M |
| Operating Cash Flow | (1.57M) | (981.03K) | (5.79M) | (22.59M) |
| Capital Expenditures | 0 | 0 | 0 | (99K) |
| Acquisitions (Net) | 0 | 0 | 0 | (5.14M) |
| Purchases of Investments | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (5.24M) |
| Debt Repayment | 400K | 766.94K | 321.43K | 17.75M |
| Common Stock Issued | 0 | 255.41K | 6.05M | 27.59M |
| Common Stock Repurchased | 0 | 0 | (166.51K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.22M | 0 | 0 | 0 |
| Financing Cash Flow | 1.62M | 1.02M | 6.21M | 45.34M |
| Effect of Forex Changes | 0 | 0 | 0 | (443) |
| Net Change in Cash | 55.07K | 41.32K | 417.05K | 17.51M |
| Free Cash Flow | (1.57M) | (981.03K) | (5.79M) | (22.69M) |
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.